Literature DB >> 15073733

Drugs and colon cancer.

G D Friedman1, A O Coates, J D Potter, M L Slattery.   

Abstract

In a case-control study of colon cancer conducted in three geographic regions of the United States, 1993 case subjects and 2410 control subjects were interviewed. In addition to queries regarding other known or suspected risk factors, subjects were asked about their use of eight drugs or drug groups. Two of these, aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs), have been inversely associated with risk in other studies. Three others--asthma medications, digitalis preparations, and phenmetrazine--were positively associated and the last three--diazepam, penicillin, and phenformin--were negatively associated with risk of colon cancer in an earlier study that screened pharmaceuticals for possible carcinogenic effects. Reported use of aspirin and NSAIDs were both inversely related to risk with essentially the same odds ratios (0.7, 95% confidence interval 0.6-0.8) for both drugs in both univariate and multivariate analyses controlling for use of each other and for other colon cancer risk factors. Subdivision by age at starting the drug, duration of use, latency interval, sex, race, family history of colon cancer, or proximal versus distal cancer revealed no substantial differences among subgroups for either aspirin or NSAIDs, but reduced risk was associated primarily with recent aspirin use. Phenformin showed a strong positive association but the data concerning this drug appeared to be inaccurate. The other drugs and drug groups showed essentially no association with colon cancer risk. Copyright 1998 John Wiley & Sons, Ltd.

Entities:  

Year:  1998        PMID: 15073733     DOI: 10.1002/(SICI)1099-1557(199803/04)7:2<99::AID-PDS320>3.0.CO;2-0

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  17 in total

1.  Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer.

Authors:  Andrew T Chan; Edward L Giovannucci; Jeffrey A Meyerhardt; Eva S Schernhammer; Gary C Curhan; Charles S Fuchs
Journal:  JAMA       Date:  2005-08-24       Impact factor: 56.272

2.  COX-1 (PTGS1) and COX-2 (PTGS2) polymorphisms, NSAID interactions, and risk of colon and rectal cancers in two independent populations.

Authors:  Karen W Makar; Elizabeth M Poole; Alexa J Resler; Brenna Seufert; Karen Curtin; Sarah E Kleinstein; David Duggan; Richard J Kulmacz; Li Hsu; John Whitton; Christopher S Carlson; Christine F Rimorin; Bette J Caan; John A Baron; John D Potter; Martha L Slattery; Cornelia M Ulrich
Journal:  Cancer Causes Control       Date:  2013-12       Impact factor: 2.506

3.  Prediagnostic non-steroidal anti-inflammatory drug use and survival after diagnosis of colorectal cancer.

Authors:  Anna E Coghill; Polly A Newcomb; Peter T Campbell; Andrea N Burnett-Hartman; Scott V Adams; Elizabeth M Poole; John D Potter; Cornelia M Ulrich
Journal:  Gut       Date:  2010-11-04       Impact factor: 23.059

4.  Genetic and lifestyle influence on telomere length and subsequent risk of colon cancer in a case control study.

Authors:  Andrew J Pellatt; Roger K Wolff; Abbie Lundgreen; Richard Cawthon; Martha L Slattery
Journal:  Int J Mol Epidemiol Genet       Date:  2012-08-31

Review 5.  Primary prevention of colorectal cancer.

Authors:  Andrew T Chan; Edward L Giovannucci
Journal:  Gastroenterology       Date:  2010-06       Impact factor: 22.682

Review 6.  [Epidemiological studies for evaluating the role of cyclooxygenase in chemoprevention of malignant tumors].

Authors:  Eva S Schernhammer; Christian Dittrich
Journal:  Wien Med Wochenschr       Date:  2003

7.  Colon tumor mutations and epigenetic changes associated with genetic polymorphism: insight into disease pathways.

Authors:  Martha L Slattery; Roger K Wolff; Karen Curtin; Frank Fitzpatrick; Jennifer Herrick; John D Potter; Bette J Caan; Wade S Samowitz
Journal:  Mutat Res       Date:  2008-10-15       Impact factor: 2.433

8.  Tumor markers and rectal cancer: support for an inflammation-related pathway.

Authors:  Martha L Slattery; Roger K Wolff; Jennifer Herrick; Bette J Caan; Wade Samowitz
Journal:  Int J Cancer       Date:  2009-10-01       Impact factor: 7.396

9.  Morbidity risks among older adults with pre-existing age-related diseases.

Authors:  Igor Akushevich; Julia Kravchenko; Svetlana Ukraintseva; Konstantin Arbeev; Alexander Kulminski; Anatoliy I Yashin
Journal:  Exp Gerontol       Date:  2013-09-21       Impact factor: 4.032

10.  Use of nonsteroidal antiinflammatory drugs and distal large bowel cancer in whites and African Americans.

Authors:  Sangmi Kim; Christopher Martin; Joseph Galanko; John T Woosley; Jane C Schroeder; Temitope O Keku; Jessie A Satia; Susan Halabi; Robert S Sandler
Journal:  Am J Epidemiol       Date:  2008-10-21       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.